Alnylam Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Alnylam Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Alnylam Pharmaceuticals Inc Strategy Report
- Understand Alnylam Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Alnylam Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Alnylam Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Dec 2020 | Lorem |
| Sanofi and Alnylam’s fitusiran for hemophilia A and B has experts mixed on likely Phase III safety profile and approval prospects due to thrombotic events | 24 Feb 2020 | Ayisha Sharma |
| Alnylam’s Phase I/II ALN-AAT02 has logical RNAi mechanism for A1AT-deficiency liver disease but risk of lung issues, off-target effects a possibility, experts say | 09 Jul 2019 | Reynald Castaneda |
| Alnylam’s early lumasiran data provides optimism for Phase III primary hyperoxaluria type 1 surrogate endpoint, but clinical outcomes beyond Phase III key for long-term use, experts say | 28 Jun 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer